5.62
0.12 (2.18%)
| Previous Close | 5.50 |
| Open | 5.23 |
| Volume | 14,904 |
| Avg. Volume (3M) | 45,501 |
| Market Cap | 171,371,216 |
| Price / Sales | 4.96 |
| 52 Weeks Range |
| Profit Margin | -205.46% |
| Operating Margin (TTM) | -95.21% |
| Diluted EPS (TTM) | -1.92 |
| Quarterly Revenue Growth (YOY) | 41.50% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -43.78 M |
| Levered Free Cash Flow (TTM) | -28.84 M |
| Return on Assets (TTM) | -92.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | TriSalus Life Sciences, Inc. | Mixed | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 5.0 |
| Average | 0.88 |
|
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 54.94% |
| % Held by Institutions | 13.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wealthcare Advisory Partners Llc | 31 Dec 2024 | 643,740 |
| Graypoint Llc | 31 Dec 2024 | 120,355 |
| Msd Partners, L.P. | 31 Dec 2024 | 39,999 |
| Connecticut Wealth Management, Llc | 31 Dec 2024 | 22,303 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (Roth MKM, 95.73%) | Buy |
| 11.00 (Canaccord Genuity, 95.73%) | Buy | |
| Median | 11.00 (95.73%) | |
| Low | 10.00 (Lake Street, 77.94%) | Buy |
| Average | 10.67 (89.86%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 5.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 28 Mar 2025 | 11.00 (95.73%) | Buy | 5.62 |
| Lake Street | 13 Feb 2025 | 10.00 (77.94%) | Buy | 5.53 |
| Roth MKM | 24 Jan 2025 | 11.00 (95.73%) | Buy | 5.18 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |